Compare Dow Inc (DOW) vs Pfizer Inc (PFE) Price & Performance

DOW trades at $27.77, down 1.38% with bearish technical signals. The company shows mixed fundamentals with negative net income margin of -3.13% and ROE of -7.86%, though recent earnings have beaten expectations. Cash flow trends show operational improvement from $1.03B in 2025 to projected $3.9B in 2026. Analyst consensus is mixed with 27.8% buy ratings and a $34.22 price target, representing 23% upside potential.

While DOW faces margin pressures and declining revenue, the stock trades at attractive valuation multiples with P/S of 0.48. The dividend remains intact with $0.35 payment scheduled for September 2026. Key risks include ongoing profitability challenges and chemical sector headwinds, but earnings beats and cash flow improvement provide potential catalysts for patient investors.

Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.

Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.